Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,686 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-interventional Study Evaluating the Mobilization of Stem Cells by Plerixafor Before Salvage Autologous Stem Cell Transplant in Relapsed Multiple Myeloma (IFM-2015-03).
van de Wyngaert Z, Malard F, Hulin C, Caillot D, Mariette C, Facon T, Touzeau C, Perrot A, Moreau P, Hebraud B, Kanouni T, Heshmati F, Lebon D, Mohty M, Chabannon C. van de Wyngaert Z, et al. Among authors: moreau p. Clin Hematol Int. 2023 Mar;5(1):38-42. doi: 10.1007/s44228-023-00030-0. Epub 2023 Feb 12. Clin Hematol Int. 2023. PMID: 36781774 Free PMC article.
Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
Moreau P, Fiere D, Bezwoda WR, Facon T, Attal M, Laporte JP, Colombat P, Haak HL, Monconduit M, Lockhorst H, Girault D, Harousseau JL. Moreau P, et al. J Clin Oncol. 1997 Feb;15(2):660-6. doi: 10.1200/JCO.1997.15.2.660. J Clin Oncol. 1997. PMID: 9053491 Clinical Trial.
Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients.
Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N, Harousseau JL. Moreau P, et al. Br J Haematol. 1998 Jun;101(4):766-9. doi: 10.1046/j.1365-2141.1998.00772.x. Br J Haematol. 1998. PMID: 9674753 Free article.
Thalidomide in patients with advanced multiple myeloma.
Yakoub-Agha I, Moreau P, Leyvraz S, Berthou C, Payen C, Dumontet C, Grosbois B, Beris P, Duguet C, Attal M, Harousseau JL, Facon T; Intergroupe Francophone du Myélome (IFM). Yakoub-Agha I, et al. Among authors: moreau p. Hematol J. 2000;1(3):186-9. doi: 10.1038/sj.thj.6200031. Hematol J. 2000. PMID: 11920188 Clinical Trial.
Heterogeneity of t(4;14) in multiple myeloma. Long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials.
Moreau P, Attal M, Garban F, Hulin C, Facon T, Marit G, Michallet M, Doyen C, Leyvraz S, Mohty M, Wetterwald M, Mathiot C, Caillot D, Berthou C, Benboubker L, Garderet L, Chaleteix C, Traullé C, Fuzibet JG, Jaubert J, Lamy T, Casassus P, Dib M, Kolb B, Dorvaux V, Grosbois B, Yakoub-Agha I, Harousseau JL, Avet-Loiseau H; SAKK; IFM Group. Moreau P, et al. Leukemia. 2007 Sep;21(9):2020-4. doi: 10.1038/sj.leu.2404832. Epub 2007 Jul 12. Leukemia. 2007. PMID: 17625611
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone.
Avet-Loiseau H, Soulier J, Fermand JP, Yakoub-Agha I, Attal M, Hulin C, Garderet L, Belhadj K, Dorvaux V, Minvielle S, Moreau P; IFM and MAG groups. Avet-Loiseau H, et al. Among authors: moreau p. Leukemia. 2010 Mar;24(3):623-8. doi: 10.1038/leu.2009.273. Epub 2010 Jan 14. Leukemia. 2010. PMID: 20072152
Stem cell collection in patients with de novo multiple myeloma treated with the combination of bortezomib and dexamethasone before autologous stem cell transplantation according to IFM 2005-01 trial.
Moreau P, Hulin C, Marit G, Caillot D, Facon T, Lenain P, Berthou C, Pégourié B, Stoppa AM, Casassus P, Michallet M, Benboubker L, Maisonneuve H, Doyen C, Leyvraz S, Mathiot C, Avet-Loiseau H, Attal M, Harousseau JL; IFM group. Moreau P, et al. Leukemia. 2010 Jun;24(6):1233-5. doi: 10.1038/leu.2010.82. Epub 2010 Apr 29. Leukemia. 2010. PMID: 20428201 Clinical Trial. No abstract available.
Prognostic impact of 18F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: a retrospective study from the GOELAMS group.
Bodet-Milin C, Touzeau C, Leux C, Sahin M, Moreau A, Maisonneuve H, Morineau N, Jardel H, Moreau P, Gallazini-Crépin C, Gries P, Gressin R, Harousseau JL, Mohty M, Moreau P, Kraeber-Bodere F, Le Gouill S. Bodet-Milin C, et al. Among authors: moreau p, moreau a. Eur J Nucl Med Mol Imaging. 2010 Aug;37(9):1633-42. doi: 10.1007/s00259-010-1469-2. Epub 2010 Apr 29. Eur J Nucl Med Mol Imaging. 2010. PMID: 20428863
Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience.
Lapierre V, Rossi JF, Heshmati F, Azar N, Vekhof A, Makowski C, Moreau P, Caillot D, Auperin A, Chabannon C. Lapierre V, et al. Among authors: moreau p. Bone Marrow Transplant. 2011 Jul;46(7):936-42. doi: 10.1038/bmt.2010.231. Epub 2010 Oct 18. Bone Marrow Transplant. 2011. PMID: 20956952
1,686 results